Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Eptinezumab Treatment Initiated During a Migraine Attack Prolonged the Time to Next Migraine and Improved HIT-6 Outcomes in the RELIEF Study
Headache
Headache Posters (7:00 AM-5:00 PM)
022

Eptinezumab, a humanized anti?calcitonin gene-related peptide monoclonal antibody, is approved in the US for the preventive treatment of migraine in adults.

To evaluate the effect of eptinezumab on time to next migraine and the 6-item Headache Impact Test (HIT-6) when administered during a moderate to severe migraine in patients considered candidates for preventive therapy.

RELIEF was a parallel-group, double-blind, randomized, placebo-controlled study (NCT04152083). Eligible patients were aged 18–75 years and had migraine 4–15 days/month in the 3 months prior to screening. Patients were randomly assigned (1:1) to infusion with eptinezumab 100mg or placebo within 1–6 hours of qualifying migraine start. Primary and secondary endpoints evaluated efficacy over the first 48 hours and safety, which are presented separately. Exploratory endpoints reported herein included time to next migraine (from day 3 to the start of the next migraine as reported by the patient) and change from baseline to Week 4 in HIT-6 total score.

The eptinezumab and placebo groups comprised 238 and 242 patients, respectively. The median time to next migraine was 10 days in the eptinezumab group and 5 days in the placebo group (hazard ratio=0.60; P<0.0001). Mean HIT-6 total scores at the screening visit indicated severe life impact (eptinezumab, 65.1; placebo, 64.8). At 4 weeks post-infusion, eptinezumab demonstrated clinically meaningful improvement in HIT-6 total score compared with placebo (mean change from baseline: eptinezumab, -8.7; placebo, -4.5; mean [95%CI] difference from placebo: -4.2 [-5.75, -2.63], P<0.0001).

In candidates for preventive migraine therapy, results from the RELIEF study showed that the preventive treatment eptinezumab delayed the time to next migraine vs placebo even when initiated during a migraine attack. In addition, HIT-6 results demonstrated clinically meaningful reductions in patient-reported and migraine-related impact over 4 weeks following eptinezumab versus placebo infusion.

Authors/Disclosures
Peter J. McAllister, MD, FAAN (New England Inst for Neurology and Headache)
PRESENTER
Dr. McAllister has received personal compensation for serving as an employee of Revance. Dr. McAllister has received personal compensation for serving as an employee of AbbVie. Dr. McAllister has received personal compensation for serving as an employee of Merz. Dr. McAllister has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aeon. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for lilly. Dr. McAllister has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for teva. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for abbvie. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for biohaven. Dr. McAllister has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for lundbeck.
Paul Winner, DO, FAAN (Palm Beach Headache Ctr) Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck . Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for lilly. The institution of Dr. Winner has received research support from Amgen. The institution of Dr. Winner has received research support from Allergan. The institution of Dr. Winner has received research support from Lundbeck . The institution of Dr. Winner has received research support from Novartis. The institution of Dr. Winner has received research support from Lilly. The institution of Dr. Winner has received research support from Teva. The institution of Dr. Winner has received research support from Supernus. The institution of Dr. Winner has received research support from Biogen. The institution of Dr. Winner has received research support from Avinar. The institution of Dr. Winner has received research support from SAMUS.
George Chakhava, MD, PhD (Multiprofile Clinic Consilium Medulla) Prof. Chakhava has nothing to disclose.
Jessica Ailani, MD, FAAN (Medstar Georgetown Neurology) Dr. Ailani has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Allergan/Abbvie. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as a Consultant for Amgen. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GlaxoSmithKline. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Gore. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merz. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurolief. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scilex. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dr. Reddy. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eneura. Dr. Ailani has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Linpharma. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Report. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medscape. The institution of Dr. Ailani has received research support from Satsuma. The institution of Dr. Ailani has received research support from Ipsen. The institution of Dr. Ailani has received research support from Parema. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Medical Advisor with SELF.
Roger Cady, MD (RK Consulting, LLC) Dr. Cady has received personal compensation for serving as an employee of Lundbeck. Dr. Cady has stock in Alder Biopharmaceutical.
Anders Ettrup (H. Lundbeck A/S) Anders Ettrup has received personal compensation for serving as an employee of H. Lundbeck A/S.
Mette Josiassen Mette Josiassen has received personal compensation for serving as an employee of Lundbeck. Mette Josiassen has received personal compensation in the range of $0-$499 for serving as a Lecturer with University of Copenhagen.
Annika Lindsten (H Lundbeck A/S) Annika Lindsten has received personal compensation for serving as an employee of H Lundbeck A/S.
Lahar R. Mehta, MD Dr. Mehta has received personal compensation for serving as an employee of Amylyx Pharmaceuticals.